These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 28758810)
61. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Rotondi M; Labriola D; Rotondi M; Ammaturo FP; Amato G; Carella C; Izzo A; Panariello S Eur J Gynaecol Oncol; 2002; 23(6):523-6. PubMed ID: 12556096 [TBL] [Abstract][Full Text] [Related]
62. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Sharifi R; Bruskewitz RC; Gittleman MC; Graham SD; Hudson PB; Stein B Clin Ther; 1996; 18(4):647-57. PubMed ID: 8879893 [TBL] [Abstract][Full Text] [Related]
64. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K; Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922 [TBL] [Abstract][Full Text] [Related]
65. Injection-site granulomas resulting from the administration of both leuprorelin acetate and goserelin acetate for the treatment of prostatic cancer. Shiota M; Tokuda N; Kanou T; Yamasaki H J Nippon Med Sch; 2007 Aug; 74(4):306-8. PubMed ID: 17878701 [TBL] [Abstract][Full Text] [Related]
66. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. Chrisp P; Sorkin EM Drugs Aging; 1991; 1(6):487-509. PubMed ID: 1794035 [TBL] [Abstract][Full Text] [Related]
67. Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis. Matalliotakis IM; Arici A; Goumenou AG; Katassos T; Karkavitsas N; Koumantakis EE Int J Fertil Womens Med; 2004; 49(2):75-8. PubMed ID: 15188832 [TBL] [Abstract][Full Text] [Related]
68. Long-term suppression of pituitary-gonadal function with three-month depot of leuprorelin acetate in a girl with central precocious puberty. Schroeter M; Baus I; Sippell WG; Partsch CJ Horm Res; 2002; 58(6):292-6. PubMed ID: 12446994 [TBL] [Abstract][Full Text] [Related]
69. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group. Bischoff W J Int Med Res; 1990; 18 Suppl 1():103-13. PubMed ID: 2108882 [TBL] [Abstract][Full Text] [Related]
70. Eligard: leuprolide acetate in a novel sustained-release delivery system. Sartor O Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884 [TBL] [Abstract][Full Text] [Related]
71. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]. Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015 [TBL] [Abstract][Full Text] [Related]
72. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report. Chang JI; Bucci J J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000 [TBL] [Abstract][Full Text] [Related]
73. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Fernandez del Moral P; Dijkman GA; Debruyne FM; Witjes WP; Kolvenbag GJ Urology; 1996 Dec; 48(6):894-900. PubMed ID: 8973673 [TBL] [Abstract][Full Text] [Related]
74. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group. Bono AV; DiSilverio F; Robustelli della Cuna G; Benvenuti C; Brausi M; Ferrari P; Gibba A; Galli L Urol Int; 1998; 60 Suppl 1():18-24. PubMed ID: 9563140 [TBL] [Abstract][Full Text] [Related]
75. Formulation study of leuprorelin acetate to improve clinical performance. Toguchi H Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592 [TBL] [Abstract][Full Text] [Related]